^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CT071

    i
    Other names: CT071, CT 071, CT-071
    Associations

    News

    Trials
    Company:
    CARsgen
    Drug class:
    GPRC5D-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    11ms
    CT071-CG7001: Study of CT071 Injection in RRMM or PPCL (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Shanghai Changzheng Hospital | N=30 --> 20 | Trial completion date: Nov 2024 --> Jul 2025 | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2024 --> Jul 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CT071
    over1year
    Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P1, N=10, Recruiting, Shanghai Changzheng Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CT071
    over1year
    Study of CT071 Injection in RRMM or PPCL (clinicaltrials.gov)
    P1, N=30, Recruiting, Shanghai Changzheng Hospital | N=18 --> 30
    Enrollment change
    |
    CT071
    over1year
    Study of CT071 Injection in HRNDMM (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Shanghai Changzheng Hospital
    New P1 trial
    |
    CT071
    over1year
    Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL (clinicaltrials.gov)
    P1/2, N=166, Not yet recruiting, CARsgen Therapeutics Co., Ltd.
    New P1/2 trial • CAR T-Cell Therapy
    |
    CT071
    over2years
    Study of CT071 Injection in RRMM or PPCL (clinicaltrials.gov)
    P1, N=18, Recruiting, Shanghai Changzheng Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CT071